Mechanisms of pharmacodynamic drug-drug interactions, including (a) beneficial interactions (e.g. additive Efficacy); (b) Increased toxicity (e.g. shared toxicity) which methods are used to assess the potential for such interactions during drug development (preclinical, clinical)? Use aleast one relevant example for the two principles.